Skip to content
Finance Investment

Renown Lending Appoints Oyishi Haque as BDM for NSW, Queensland and Western Australia

Renown Lending < 1 mins read
Key Facts:
  • New appointment: Business Development Manager

  • Coverage: NSW, Queensland & Western Australia

  • Specialisation: Asset-backed lending

  • Background: Macquarie Group, Alex.Bank, ScotPac, Plenti, GetCapital

  • Commencement: New Year

  • Focus: Broker partnerships, complex and time-critical lending solutions


Oyishi joins Renown Lending with more than eight years’ experience across banking, non-bank lending and third-party distribution. She has held senior BDM and relationship management roles with Alex.Bank, ScotPac Business Finance, Plenti, GetCapital and Macquarie Group, working closely with brokers, introducers and professional advisers across secured and unsecured lending.

At Renown Lending, Oyishi will specialise in asset-backed lending, working with brokers on solutions spanning first and second mortgages, commercial property, construction, land, and bespoke non-bank structures where speed, certainty and flexibility matter most.

Her appointment supports Renown Lending’s continued national growth and its focus on delivering fast, ethical and commercially sound funding outcomes for clients who do not fit traditional bank criteria.

Oyishi will officially commence in the New Year and will be engaging with brokers across NSW, Queensland and Western Australia to introduce Renown Lending’s asset-backed lending capabilities and investor-led funding solutions.


About us:

Renown Lending is an Australian non-bank lender specialising in asset-backed lending solutions for brokers, investors, developers and SMEs. The business provides first and second mortgages, construction finance, land funding and bespoke private credit solutions, with a focus on speed, certainty and transparent execution. Renown Lending works nationally with brokers to support clients who require flexible funding beyond traditional bank models.

Media

More from this category

  • Finance Investment
  • 13/01/2026
  • 13:40
Moomoo

Focused on AI, Australian investors expect 2026 to deliver

SYDNEY, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Australian investors have started the new year with an overwhelming appetite for artificial intelligence and expectations of solid returns from their increasingly global portfolios, a comprehensive new survey by stock broking firm Moomoo Australia and New Zealand reveals.The detailed survey of more than 600 Australian investors' expectations and intentions for the year complements the release of moomoo's 2026 Market Outlook today, where our local experts and global research team analyse key trends in financial markets for the year ahead.And this year, investors are committing to high-growth sectors, including AI – showing a willingness…

  • Finance Investment, Oil Mining Resources
  • 13/01/2026
  • 10:22
Jane Morgan Management

Patriot Resources reports significant silver and gold results validating Kitumba polymetallic target in Zambia

Perth, Australia – 13 January 2026: Patriot Resources Limited (ASX: PAT) has reported significant silver and gold assay results from its Phase 1 trenching program at Target B1 within the Company’s 80%-owned Kitumba 27715 Project in Zambia, further validating the prospect as a near-surface polymetallic system. The latest results add silver and gold credits to previously announced strong copper, zinc and lead geochemistry, reinforcing the scale and potential economic significance of the mineralised system. The Company said the combination of metals highlights a unique polymetallic signature and strengthens confidence in Target B1 as a priority focus for ongoing exploration. Notable…

  • Contains:
  • Finance Investment, Medical Health Aged Care
  • 13/01/2026
  • 10:09
Jane Morgan Management

NeuroScientific Biopharmaceuticals (ASX:NSB) Reports Clinical Response for StemSmart(TM) Treatment in Fistulising Crohn’s Disease Under Special Access Program

13 January 2026 – Perth, Australia | NeuroScientific Biopharmaceuticals Limited (ASX:NSB) has today announced a “Clinical Response” from patients treated with its patented StemSmart™ Mesenchymal Stem Cell (MSC) therapy under the Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS) for fistulising Crohn’s disease. Three of four patients treated in Cohort 1 of the Special Access Program demonstrated a successful “Clinical Response” following treatment with StemSmart™, with the fourth patient showing a partial response with further clinical assessment needed. A Clinical Response is defined as either closure of at least 50 per cent of fistula openings or a reduction in fistula…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.